Genetics of Oral Semaglutide Response in Prediabetes and Obesity Explored

The global prevalence of prediabetes and obesity continues to rise, necessitating effective and personalized treatment strategies. Oral semaglutide, a GLP-1 receptor agonist, has shown significant efficacy in improving metabolic parameters and promoting weight loss. However, individual responses to this medication can vary widely, and the underlying genetic factors contributing to these differential responses remain largely unknown.

As an ongoing study, specific results are not yet available. However, the study aims to identify genetic markers associated with significant improvements in metabolic parameters, potentially revealing differential responses to oral semaglutide treatment. Researchers anticipate correlating specific genetic variations with the magnitude of HbA1c reduction, body weight loss, and improvements in insulin sensitivity. They expect to observe varying degrees of liver steatosis reduction and body composition changes across genetically distinct groups. The primary objective is to pinpoint specific genetic variations that predict an individual's metabolic response to oral semaglutide, including reductions in HbA1c and body weight, and improvements in insulin sensitivity, potentially revealing distinct genetic profiles for responders versus non-responders.